Ivonescimab and cadonilimab plus chemo for extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer that has spread widely.
- You should not have had any previous chemotherapy or immunotherapy for this cancer.
- You must be between 18 and 75 years old.
- You must be able to provide a tumor sample from a biopsy.
- You must agree to use effective birth control during and for 120 days after treatment (if you can have children).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
This study tests a new immunotherapy drug called ivonescimab for people with extensive-stage small cell lung cancer who have not had treatment before. The goal is to see if it can help shrink tumors and improve survival.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.